title: Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
abstract: An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20-30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to < 400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a > or = 24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV-1 RNA to < 400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.
authors.affiliation: Department of Pediatrics, UCLA, Los Angeles, California, 90095-3075, USA. pkrogsta@pediatrics.medsch.ucla.edu
authors.forename: P
authors.initials: P
authors.lastname: Krogstad
authors.forename: A
authors.initials: A
authors.lastname: Wiznia
authors.forename: K
authors.initials: K
authors.lastname: Luzuriaga
authors.forename: W
authors.initials: W
authors.lastname: Dankner
authors.forename: K
authors.initials: K
authors.lastname: Nielsen
authors.forename: M
authors.initials: M
authors.lastname: Gersten
authors.forename: B
authors.initials: B
authors.lastname: Kerr
authors.forename: A
authors.initials: A
authors.lastname: Hendricks
authors.forename: B
authors.initials: B
authors.lastname: Boczany
authors.forename: M
authors.initials: M
authors.lastname: Rosenberg
authors.forename: D
authors.initials: D
authors.lastname: Jung
authors.forename: S A
authors.initials: SA
authors.lastname: Spector
authors.forename: Y
authors.initials: Y
authors.lastname: Bryson
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D008297:Male; D019888:Nelfinavir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir